Bortezomib-Induced Acute Pancreatitis
DOI:
https://doi.org/10.6092/1590-8577/3829Keywords:
bortezomib, Drug toxicity, PancreatitisAbstract
No abstract available.
Image: Illustration of the proteasome inhibitor bortezomib bound to an assembled yeast proteasome core (PDB ID 2F16). (Author: Opabinia regalis; Wikimedia Commons)
Downloads
References
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed refractory myeloma. N Engl J Med 2003; 384:2609-17. [PMID 12826635]
Popat R, Joel S, Oakervee H, Cavenagh J. Bortezomib for multiple myeloma. Expert Opin Pharmacother 2006; 7:1337-46. [PMID 16805719]
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-45. [PMID 7249508]
Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf 2008; 31:823-37. [PMID 18759507]
Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007; 5:648-61. [PMID 17395548]
Szabolcs A, Biczó G, Rakonczay Z, Tiszlavicz L, Halm G, Wittmann T, Takács T. Simultaneous proteosome inhibition and heat shock protein induction by bortezomib is beneficial in experimental pancreatitis. Eur J Pharmacol 2009; 616:270-4. [PMID 19486901]
